Clinical Trial Update: Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fesoterodine sustained release for overactive bladder has completed, assessing efficacy, tolerability, and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Toviaz (fesoterodine fumarate)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder | Phase 3 | Status: COMPLETED